Estados Unidos · Plataformas y datos · Morningstar

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

Publicado por Morningstar · Estados Unidos hace 8 h

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

También te puede interesar

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Where Classic Design Meets User Creativity: iCAUR Interprets “Classic Never Fades”

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

Compartir

También te puede interesar

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Where Classic Design Meets User Creativity: iCAUR Interprets “Classic Never Fades”